Hemant Surgical Industries Limited has entered into a strategic C-ARM Development and Supply Agreement with GBT Korea Co., Ltd., Republic of Korea, as announced through a regulatory filing under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The agreement was disclosed on April 02, 2026, and signed by Managing Director Hanskumar Shamji Shah.

Partnership Objectives and Technology Focus

The collaboration is designed to leverage GBT Korea's strong technological expertise in developing and localizing advanced medical imaging equipment. The partnership will focus on three key technological areas:

• X-ray generators development and localization
• Electronic control systems for medical imaging
• C-arm imaging devices utilizing fluoroscopy x-ray technology

These imaging systems are specifically designed to provide real-time high-resolution imaging during critical surgical procedures, including orthopedic, trauma, and cardiovascular operations.

Agreement Structure and Terms

Regulatory Compliance and Disclosures

The company has confirmed that this agreement does not fall within related party transactions framework. Key regulatory aspects include:

• No shareholding arrangements between the parties
• No special rights provisions such as director appointment rights
• No share subscription or capital structure restrictions
• Arms-length transaction structure maintained

The agreement does not involve any share issuance, loan arrangements, or other financial instruments. Both parties have agreed to maintain confidentiality regarding the financial size of the agreement.

Strategic Implications

This partnership represents Hemant Surgical Industries' strategic move to enhance its technological capabilities in the medical imaging sector. The collaboration with GBT Korea aims to bring advanced fluoroscopy technology to the Indian market, potentially strengthening the company's position in surgical equipment manufacturing.

The agreement focuses on developing imaging solutions that provide real-time visualization capabilities, which are crucial for precision in modern surgical procedures across orthopedic, trauma, and cardiovascular specialties.

Hemant Surgical Industries Limited has announced the execution of a strategic Semi Knocked Down (SKD) Manufacturing Agreement with Sonomed Escalon, USA, marking a significant step in the company's expansion into ophthalmic diagnostic device manufacturing. The agreement was disclosed under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Agreement Overview

The partnership with Sonomed Escalon, a global leader in ophthalmic diagnostic imaging, focuses on the manufacturing of ophthalmic ultrasound diagnostic devices. The agreement encompasses both SKD manufacturing and plans for further localization to achieve 100% manufacturing capabilities in India.

Commercial Terms and Structure

Under the SKD Manufacturing Agreement, both parties have defined their scope of work for SKD operations and subsequent localization efforts. Sonomed Escalon has agreed to supply components in SKD form at preferential transfer pricing, providing cost advantages for the manufacturing process.

The pricing structure excludes several cost components:

• Taxes, duties, and customs charges
• Statutory levies
• Shipping costs (unless otherwise agreed)

Regulatory Compliance and Disclosures

The company confirmed that this transaction does not fall under related party transactions, despite the fact that the promoter was previously an authorized distributor of Sonomed Escalon. The agreement does not involve any shareholding arrangements between the parties, and no special rights such as director appointments or share subscription rights are included.

Strategic Implications

This manufacturing agreement represents Hemant Surgical Industries' strategic move to expand its capabilities in the ophthalmic diagnostic equipment sector. The partnership with an established global leader like Sonomed Escalon provides access to advanced technology and manufacturing expertise in specialized medical devices.

The phased approach from SKD manufacturing to complete localization aligns with India's manufacturing initiatives and could position the company as a significant player in the domestic ophthalmic diagnostic device market. The preferential pricing structure from Sonomed Escalon enhances the commercial viability of this manufacturing venture.